Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novocure shares soar 33% as FDA approves lung cancer treatment
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 i
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors (immunotherapy) or docetaxel to treat metastatic non–small cell lung cancer that has not responded to platinum-based treatment.
I Still Reflect on My Lung Cancer Treatment Decisions
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for immunotherapy.
Novocure Shares Rise After FDA Approves Optune Lua Cancer Treatment
Shares of Novocure were trading higher in Tuesday's late session after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung cancer.
Novocure gets FDA approval for its lung cancer treatment
Novocure (NASDAQ:NVCR) shares rose 6% after market on announcing U.S. FDA approval for Optune Lua for the treatment of adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.
Yahoo Finance
11h
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/
PD-L1
inhibitors or docetaxel ...
Targeted Oncology
9h
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
GlobalData on MSN
1d
Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint
Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
EurekAlert!
15d
FOXM1 and PD-L1 in CDK4/6-MEK resistance in nerve tumors
A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...
emjreviews.com
1d
New Imaging Technique Shows Promise for Personalised Oesophageal Cancer Treatment – UEG Week 2024
Discover a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced ...
Targeted Oncology
8d
Long-Term Data Confirms Cemiplimab Benefits in High PD-L1 NSCLC
Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...
Future Market Insights
12d
Global PD-1/PD-L1 Inhibitors Market Set to Reach USD 123.3 Billion by 2033, Growing at a 9.6% CAGR
The global PD-1/PD-L1 inhibitors market is projected to witness remarkable growth over the next decade, with an estimated ...
Armed robbery in Revesby
15d
FOXM1, PD-L1 Linked to CDK4/6-MEK Resistance in Nerve Tumors
We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Optune Lua
Exelixis
Food and Drug Administration
zanzalintinib
Pembrolizumab
Feedback